Tyrosine aminotransferase: biochemical and structural properties and molecular dynamics simulations

被引:38
作者
Mehere, Prajwalini [1 ]
Han, Qian [1 ]
Lemkul, Justin A. [1 ]
Vavricka, Christopher J. [1 ,2 ]
Robinson, Howard [3 ]
Bevan, David R. [1 ]
Li, Jianyong [1 ]
机构
[1] Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA
[2] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogenic Microbiol & Immunol, Beijing 100101, Peoples R China
[3] Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA
关键词
tyrosine aminotransferase; crystal structure; substrate specificity; tyrosine; tyrosinemia; RICHNER-HANHART-SYNDROME; PARTICLE MESH EWALD; TRYPANOSOMA-CRUZI; KYNURENINE AMINOTRANSFERASE; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; FORCE-FIELD; RAT-LIVER; TAT GENE;
D O I
10.1007/s13238-010-0128-5
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Tyrosine aminotransferase (TAT) catalyzes the transamination of tyrosine and other aromatic amino acids. The enzyme is thought to play a role in tyrosinemia type II, hepatitis and hepatic carcinoma recovery. The objective of this study is to investigate its biochemical and structural characteristics and substrate specificity in order to provide insight regarding its involvement in these diseases. Mouse TAT (mTAT) was cloned from a mouse cDNA library, and its recombinant protein was produced using Escherichia coli cells and purified using various chromatographic techniques. The recombinant mTAT is able to catalyze the transamination of tyrosine using a-ketoglutaric acid as an amino group acceptor at neutral pH. The enzyme also can use glutamate and phenylalanine as amino group donors and p-hydroxyphenylpyruvate, phenylpyruvate and alpha-ketocaproic acid as amino group acceptors. Through macromolecular crystallography we have determined the mTAT crystal structure at 2.9 angstrom resolution. The crystal structure revealed the interaction between the pyridoxal-5'-phosphate cofactor and the enzyme, as well as the formation of a disulphide bond. The detection of disulphide bond provides some rational explanation regarding previously observed TAT inactivation under oxidative conditions and reactivation of the inactive TAT in the presence of a reducing agent. Molecular dynamics simulations using the crystal structures of Trypanosoma cruzi TAT and human TAT provided further insight regarding the substrate-enzyme interactions and substrate specificity. The biochemical and structural properties of TAT and the binding of its cofactor and the substrate may help in elucidation of the mechanism of TAT inhibition and activation.
引用
收藏
页码:1023 / 1032
页数:10
相关论文
共 60 条
  • [1] RICHNER-HANHART SYNDROME (TYROSINEMIA TYPE-II) - CASE-REPORT AND LITERATURE-REVIEW
    ALHEMIDAN, AI
    ALHAZZAA, SAF
    [J]. OPHTHALMIC GENETICS, 1995, 16 (01): : 21 - 26
  • [2] RECURRENT MASSIVE HEMORRHAGE FROM BENIGN HEPATIC TUMORS SECONDARY TO ORAL-CONTRACEPTIVES
    BEIN, NN
    GOLDSMITH, HS
    [J]. BRITISH JOURNAL OF SURGERY, 1977, 64 (06) : 433 - 435
  • [3] SUBCELLULAR-DISTRIBUTION OF A FACTOR INACTIVATING TYROSINE AMINOTRANSFERASE - STUDY OF ITS MECHANISM AND RELATIONSHIP TO DIFFERENT FORMS OF ENZYME
    BENEKING, M
    SCHMIDT, H
    WEISS, G
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1978, 82 (01): : 235 - 243
  • [4] Berendsen HJ, 1981, Interaction models for water in relation to protein hydration, DOI DOI 10.1007/978-94-015-7658-1_21
  • [5] MOLECULAR-DYNAMICS WITH COUPLING TO AN EXTERNAL BATH
    BERENDSEN, HJC
    POSTMA, JPM
    VANGUNSTEREN, WF
    DINOLA, A
    HAAK, JR
    [J]. JOURNAL OF CHEMICAL PHYSICS, 1984, 81 (08) : 3684 - 3690
  • [6] Blankenfeldt W, 1999, PROTEIN SCI, V8, P2406
  • [7] PARTICIPATION OF CYSTEINE AND CYSTINE IN INACTIVATION OF TYROSINE AMINOTRANSFERASE IN RAT-LIVER HOMOGENATES
    BUCKLEY, WT
    MILLIGAN, LP
    [J]. BIOCHEMICAL JOURNAL, 1978, 176 (02) : 449 - 454
  • [8] CAVELIERBALLOY B, 1985, ANN DERMATOL VENER, V112, P965
  • [9] Clinical and mutational investigations of tyrosinemia type II in Northern Tunisia: Identification and structural characterization of two novel TAT mutations
    Charfeddine, C.
    Monastiri, K.
    Mokni, M.
    Laadjimi, A.
    Kaabachi, N.
    Perin, O.
    Nilges, M.
    Kassar, S.
    Keirallah, M.
    Guediche, M. N.
    Kamoun, M. R.
    Tebib, N.
    Ben Dridi, M. F.
    Boubaker, S.
    Ben Osman, A.
    Abdelhak, S.
    [J]. MOLECULAR GENETICS AND METABOLISM, 2006, 88 (02) : 184 - 191
  • [10] Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO